[Form 4] Atlassian Corporation Insider Trading Activity
Rhea-AI Filing Summary
Atlassian (NASDAQ:TEAM) filed a Form 4 reporting that CEO, director and 10% owner Michael Cannon-Brookes sold 7,665 Class A shares on 26 Jun 2025 under a Rule 10b5-1 plan adopted 20 Feb 2025.
The five tranches were executed at weighted-average prices between $196.79 – $200.39, raising roughly $1.5 million in gross proceeds. Following the sale, Cannon-Brookes holds 15,330 Class A shares indirectly via CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust.
- No derivative transactions, option exercises or new corporate events were disclosed.
- Cannon-Brookes remains a director, CEO and 10% owner.
The filing is limited to the insider transaction and does not include operational or financial updates.
Positive
- None.
Negative
- CEO & 10% owner Michael Cannon-Brookes sold 7,665 Class A shares (~$1.5 M), reducing his trust’s holdings by roughly 33%, which may pressure near-term sentiment despite 10b5-1 pre-planning.
Insights
TL;DR: Pre-planned $1.5 M share sale; limited governance signal
The transaction represents roughly one-third of the trust’s Class A stake yet remains modest relative to Cannon-Brookes’ overall equity, including super-voting Class B shares not listed here. Execution under a 10b5-1 plan reduces informational value, indicating portfolio diversification rather than a directional view on fundamentals. The retained 15,330 shares and continuing 10% owner status suggest no impending change in control. Unless accompanied by a pattern of accelerated selling or broader C-suite disposals, the governance impact is neutral.
TL;DR: Mildly bearish sentiment, unlikely to move stock
The ~$1.5 million disposition equals under one trading day’s average volume for TEAM, limiting market impact. Price range ($196–$200) sits close to recent averages, implying no urgency. Still, insider sales—especially by a founder-CEO—often weigh on short-term sentiment. I would monitor upcoming filings for repeat sales and watch if other executives join; absent that, the sale appears routine diversification and does not alter the investment thesis.